1. Sung, H, Ferlay, J, Siegel, RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.
Google Scholar | Crossref | Medline2. IARC . Breast cancer screening, 2016, https://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Breast-Cancer-Screening-2016 (accessed 28 March 2021).
Google Scholar3. Webb, PM, Cummings, MC, Bain, CJ, et al. Changes in survival after breast cancer: improvements in diagnosis or treatment? Breast 2004; 13: 7–14.
Google Scholar | Crossref | Medline | ISI4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) . Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018; 19: 27–39.
Google Scholar | Crossref | Medline5. Chen, EY, Joshi, SK, Tran, A, et al. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern Med 2019; 179: 642–647.
Google Scholar | Crossref | Medline6. US Food and Drug Administration, NIH Biomarker Working Group . BEST (Biomarkers, EndpointS, and other Tools) resource. US Food and Drug Administration, 2016, Silver Spring, MD, http://www.ncbi.nlm.nih.gov/books/NBK326791/ (accessed 28 March 2021).
Google Scholar7. Prentice, RL . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431–440.
Google Scholar | Crossref | Medline | ISI8. US Food and Drug Administration (FDA) . FDA facts: biomarkers and surrogate endpoints. US FDA, 2019, https://www.fda.gov/about-fda/innovation-fda/fda-facts-biomarkers-and-surrogate-endpoints (accessed 28 March 2021).
Google Scholar9. Gyawali, B, Hey, SP, Kesselheim, AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med 2019; 179: 906–913.
Google Scholar | Crossref | Medline10. US Food and Drug Administration (FDA) . Table of surrogate endpoints that were the basis of drug approval or licensure. US FDA, 2020, https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure (accessed 28 March 2021).
Google Scholar11. Von Minckwitz, G, Untch, M, Blohmer, J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796–1804.
Google Scholar | Crossref | Medline | ISI12. Von Minckwitz, G, Eidtmann, H, Rezai, M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299–309.
Google Scholar | Crossref | Medline | ISI13. Baselga, J, Bradbury, I, Eidtmann, H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet Lond Engl 2012; 379: 633–640.
Google Scholar | Crossref | Medline | ISI14. Bear, HD, Tang, G, Rastogi, P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310–320.
Google Scholar | Crossref | Medline | ISI15. Mazouni, C, Peintinger, F, Wan-Kau, S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007; 25: 2650–2655.
Google Scholar | Crossref | Medline | ISI16. US Food and Drug Administration . Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry, 2018, https://www.fda.gov/media/71195/download
Google Scholar17. Houssami, N, Macaskill, P, Von Minckwitz, G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012; 48: 3342–3354.
Google Scholar | Crossref | Medline18. Cortazar, P, Zhang, L, Untch, M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet Lond Engl 2014; 384: 164–172.
Google Scholar | Crossref | Medline | ISI19. Xie, W, Halabi, S, Tierney, JF, et al. A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses. JNCI Cancer Spectr 2019; 3: pkz002.
Google Scholar | Crossref | Medline20. Saad, ED, Squifflet, P, Burzykowski, T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol 2019; 20: 361–370.
Google Scholar | Crossref | Medline21. Rotolo, F, Paoletti, X, Michiels, S. surrosurv: an R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials. Comput Methods Programs Biomed 2018; 155: 189–198.
Google Scholar | Crossref | Medline22. Petrelli, F, Borgonovo, K, Cabiddu, M, et al. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol 2017; 8: 39–48.
Google Scholar | Crossref | Medline23. Prowell, TM, Pazdur, R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366: 2438–2441.
Google Scholar | Crossref | Medline | ISI24. US Food and Drug Administration . Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval; guidance for industry; availability. Federal Register, 2014, https://www.federalregister.gov/documents/2014/10/07/2014-23845/pathological-complete-response-in-neoadjuvant-treatment-of-high-risk-early-stage-breast-cancer-use (accessed 3 April 2021).
Google Scholar25. Gianni, L, Eiermann, W, Semiglazov, V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014; 15: 640–647.
Google Scholar | Crossref | Medline | ISI26. Chumsri, S, Li, Z, Serie, DJ, et al. Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG oncology/NSABP B-31. J Clin Oncol 2019; 37: 3425–3435.
Google Scholar | Crossref | Medline27. Berruti, A, Amoroso, V, Gallo, F, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 2014; 32: 3883–3891.
Google Scholar | Crossref | Medline28. Korn, EL, Sachs, MC, McShane, LM. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer. Ann Oncol 2016; 27: 10–15.
Google Scholar | Crossref | Medline29. Broglio, KR, Quintana, M, Foster, M, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol 2016; 2: 751–760.
Google Scholar | Crossref | Medline30. Gyawali, B, Hey, SP, Kesselheim, AS. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine 2020; 21: 100332.
Google Scholar | Crossref | Medline31. Gyawali, B, D’Andrea, E, Franklin, JM, et al. A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer. EClinicalMedicine 2021; 32: 100730.
Google Scholar | Crossref | Medline32. Ng, R, Pond, GR, Tang, PA, et al. Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol 2008; 19: 481–486.
Google Scholar | Crossref | Medline33. Romond, EH, Perez, EA, Bryant, J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684.
Google Scholar | Crossref | Medline | ISI34. Von Minckwitz, G, Procter, M, de Azambuja, E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377: 122–131.
Google Scholar | Crossref | Medline35. Carioli, G, Malvezzi, M, Rodriguez, T, et al. Trends and predictions to 2020 in breast cancer mortality in Europe. Breast 2017; 36: 89–95.
Google Scholar | Crossref | Medline36. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) ;Peto, R, Davies, C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432–444.
Google Scholar | Crossref | Medline | ISI37. DeMichele, A, Yee, D, Berry, DA, et al. The neoadjuvant model is still the future for drug development in breast cancer. Clin Cancer Res 2015; 21: 2911–2915.
Google Scholar | Crossref | Medline38. Eiermann, W, Paepke, S, Appfelstaedt, J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527–1532.
Google Scholar | Crossref | Medline39. Krainick-Strobel, UE, Lichtenegger, W, Wallwiener, D, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 2008; 8: 62.
Google Scholar | Crossref | Medline | ISI40. Dowsett, M, Smith, IE, Ebbs, SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167–170.
Google Scholar | Crossref | Medline41. Elli, MJ, Suman, VJ, Hoog, J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (Alliance). J Clin Oncol 2017; 35: 1061–1069.
Google Scholar | Crossref | Medline42. Dowsett, M, Sestak, I, Lopez-Knowles, E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783–2790.
Google Scholar | Crossref | Medline | ISI43. Krop, I, Ismaila, N, Andre, F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2017; 35: 2838–2847.
Google Scholar | Crossref | Medline44. Dowsett, M, Ebbs, SR, Dixon, JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists. J Clin Oncol 2005; 23: 2477–2492.
Google Scholar | Crossref | Medline | ISI45. Robertson, JFR, Dowsett, M, Bliss, JM, et al. Abstract GS1-03: peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – the POETIC* trial (CRUK/07/015). Cancer Res 2018; 78: GS1-03.
Google Scholar | Medline46. Smith, I, Robertson, J, Kilburn, L, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 2020; 21: 1443–1454.
Google Scholar | Crossref | Medline47. E